Zacks: Brokerages Expect Icon Plc (ICLR) to Announce $1.48 EPS

Analysts expect Icon Plc (NASDAQ:ICLR) to report $1.48 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Icon’s earnings, with the highest EPS estimate coming in at $1.50 and the lowest estimate coming in at $1.46. Icon posted earnings of $1.31 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 13%. The company is scheduled to issue its next quarterly earnings results on Thursday, July 26th.

On average, analysts expect that Icon will report full-year earnings of $6.05 per share for the current financial year, with EPS estimates ranging from $6.01 to $6.07. For the next fiscal year, analysts anticipate that the firm will report earnings of $6.86 per share, with EPS estimates ranging from $6.69 to $7.05. Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Icon.

Icon (NASDAQ:ICLR) last announced its quarterly earnings results on Thursday, May 3rd. The medical research company reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.41 by $0.01. Icon had a return on equity of 26.56% and a net margin of 14.80%. The company had revenue of $620.13 million during the quarter, compared to analyst estimates of $562.61 million. During the same quarter last year, the firm posted $1.29 earnings per share. The firm’s revenue was up 43.6% on a year-over-year basis.



A number of brokerages recently commented on ICLR. KeyCorp raised their price target on Icon from $130.00 to $152.00 and gave the stock an “overweight” rating in a research note on Monday. BidaskClub raised Icon from a “buy” rating to a “strong-buy” rating in a research note on Friday. Zacks Investment Research raised Icon from a “sell” rating to a “hold” rating in a research report on Tuesday, May 8th. Finally, Credit Suisse Group raised their price objective on Icon from $131.00 to $144.00 and gave the company an “outperform” rating in a research report on Tuesday. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $131.00.

A number of institutional investors have recently made changes to their positions in ICLR. Financial Gravity Companies Inc. purchased a new position in Icon during the fourth quarter valued at $144,000. Financial Gravity Wealth Inc. bought a new position in shares of Icon during the first quarter valued at $179,000. Gotham Asset Management LLC bought a new position in shares of Icon during the fourth quarter valued at $209,000. Private Advisor Group LLC bought a new position in shares of Icon during the fourth quarter valued at $216,000. Finally, We Are One Seven LLC bought a new position in shares of Icon during the fourth quarter valued at $252,000. 87.11% of the stock is owned by institutional investors and hedge funds.

ICLR stock traded up $0.70 on Friday, reaching $137.03. The company’s stock had a trading volume of 193,400 shares, compared to its average volume of 275,117. Icon has a 12-month low of $95.06 and a 12-month high of $138.17. The firm has a market capitalization of $7.38 billion, a price-to-earnings ratio of 25.42, a PEG ratio of 2.14 and a beta of 0.44. The company has a quick ratio of 1.85, a current ratio of 1.85 and a debt-to-equity ratio of 0.29.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Get a free copy of the Zacks research report on Icon (ICLR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply